Eli Lilly and Company
Eli Lilly and Company is an American pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. Lilly has a research legacy that includes the first commercial production of insulin in the 1920s, the development of the first polio vaccine seed stock, the introduction of fluoxetine (Prozac) — one of the most prescribed antidepressants in history — and the discovery of gemcitabine for cancer. Today Lilly's clinical trial portfolio is concentrated in diabetes and obesity, oncology, immunology, and neuroscience.
In metabolic disease, Lilly's GLP-1/GIP receptor agonist tirzepatide (Mounjaro/Zepbound) has generated landmark trial data in type 2 diabetes (SURPASS program) and obesity (SURMOUNT program), with trials now expanding into heart failure, sleep apnea, non-alcoholic steatohepatitis, and chronic kidney disease. The oncology program focuses on CDK4/6 inhibition (abemaciclib/Verzenio for breast cancer), antibody-drug conjugates, and bispecific antibodies. In immunology, the IL-17 and JAK inhibition programs cover psoriasis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease.
Lilly's Alzheimer's disease program is among the most substantial in the industry. Donanemab, an anti-amyloid antibody, completed the TRAILBLAZER-ALZ 2 Phase 3 trial with positive results and has received FDA accelerated approval. Lilly continues to run trials combining anti-amyloid therapy with tau-targeting agents and lifestyle interventions. The company also participates in the Alzheimer's Clinical Trials Consortium (ACTC) and A4 Study consortium for prevention-stage research.